Related Experiment Video
Updated: Jul 9, 2026
05:59
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Eszopiclone for late-life insomnia
Christina S McCrae1, Amanda Ross, Ashley Stripling
1Department of Clinical and Health Psychology, University of Florida, PO Box 1001 65, Gainesville, FL 32610-0165, USA. cmccrae@phhp.ufl.edu
Clinical Interventions in Aging
|November 30, 2007
Summary
Eszopiclone is a safe short-term treatment for insomnia in older adults. Its long-term effectiveness and comparison to cognitive-behavioral therapy for insomnia in the elderly require further study.
Area of Science:
- Gerontology
- Pharmacology
- Sleep Medicine
Background:
- Insomnia is a prevalent sleep disturbance in older adults, affecting 20%-50%.
- Eszopiclone, a nonbenzodiazepine hypnotic, is approved for insomnia treatment.
- Limited data exist on long-term eszopiclone use in the oldest old (85+).
Purpose of the Study:
- To provide an overview of eszopiclone's literature, focusing on its use in late-life insomnia.
- To examine eszopiclone's safety, efficacy, and considerations for older adults.
- To highlight the need for comparative studies with other treatments.
Main Methods:
- Review of existing clinical trial data and literature on eszopiclone.
- Analysis of pharmacology, pharmacodynamics, and pharmacokinetics in older populations.
- Examination of adverse events, drug interactions, and tolerance.
Main Results:
- Eszopiclone is safe and effective for short-term (2-week) treatment of chronic insomnia in adults aged 64-91.
- Long-term efficacy and safety in the oldest old (75+) remain unknown.
- No direct comparisons exist between eszopiclone and cognitive-behavioral therapy for insomnia (CBT-I) in older adults.
Conclusions:
- Eszopiclone offers a safe short-term option for older adults with insomnia.
- Further research is needed to establish long-term benefits and safety profiles in the elderly.
- Cognitive-behavioral therapy for insomnia presents a viable alternative or adjunctive therapy.
Related Concept Videos
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:27Insomnia
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:07Narcolepsy
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.